Diagnostics tops new cancer network agenda in UK
This article was originally published in Clinica
Improved access to diagnostics and treatment technology is the main aim of the UK National Translational Cancer Research Network (NTRAC). Its role will be to co-ordinate the work of at least eight of the UK's most prominent scientific and clinical research institutions, with the aim of increasing the number of early clinical trials and by improving the efficiency of their assessment at national level.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.